Considerations for successful cancer immunotherapy in aged hosts

Area of Science:

• Immunology
• Oncology
• Gerontology

Background:

• Aging is the primary risk factor for cancer development.
• Current cancer immunotherapy research predominantly uses young animal models, potentially limiting translation to older populations.
• Age-associated immune system changes, termed Age Related Immune Dysfunction (ARID), profoundly affect cancer immunity.

Purpose of the Study:

• To review age-related changes in immune function relevant to cancer immune surveillance, pathogenesis, and immunotherapy.
• To highlight challenges and successes in treating cancer in aged individuals.
• To identify future research directions for optimizing cancer immunotherapy in the elderly.

Main Methods:

• Literature review focusing on age-related immune alterations and their impact on cancer.
• Analysis of how declining T cell function, shifts in immune cell populations (e.g., pro-inflammatory and myeloid-derived suppressor cells), drug effects, and the aged microenvironment influence immunotherapy outcomes.
• Synthesis of current knowledge and identification of research gaps.

Main Results:

• Aging impairs T cell function, potentially reducing immunotherapy efficacy.
• Detrimental immune changes in aging include increased pro-inflammatory cells and enhanced suppressive cell activity.
• The aged microenvironment and age-specific drug effects can further impede anti-cancer immunity.

Conclusions:

• Age Related Immune Dysfunction (ARID) presents significant challenges for cancer immunotherapy.
• Despite declining immune function, successful strategies to overcome age-related barriers in cancer treatment are emerging.
• Further research is needed to fully understand and exploit ARID for effective cancer immunotherapy in the aged.